Carbamazepine and the HLA-A*3101 and HLA-B*1502 genes
As a result of genetic variations, your body may not produce certain proteins or may produce them with an abnormal composition, potentially changing the way in which drugs are processed.
It is known, for example, that mutations in the HLA-A*3101 gene may be partly responsible for triggering a hypersensitivity reaction to a carbamazepine treatment. If you are HLA-A*3101 positive, your risk of experiencing (generally mild) side effects is significantly increased.
Mutations in the HLA-B*1502 gene can also increase the risk of side effects and these are generally more severe than those resulting from HLA-A*3101 positivity. Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with carbamazepine.